Drug pricing disruptor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm
EQRx, a would-be drug pricing disruptor that has emerged as an investor darling, has everything but an approval to show in its fight against financial toxicity in biopharma. With the homestretch closing in, the team is now ready for its close-up.
EQRx will reverse merge with the CM Life Sciences III SPAC, kickstarted by biotech blue chipper Casdin Capital and Corvex Management, and go public as part of a deal that will infuse around $1.8 billion into the drug pricing disruptor’s bank account, the partners said Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.